GNLX:NASDAQ
Genelux Corp
2,52 $
arrow_downward
-0,98%(-0,025) 1D
13 қаз., 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GNLX...
Open
2,53 $
High
2,54 $
Low
2,48 $
Mkt. cap
113,79 млн
Avg. vol.
249,28 м.
Volume
0,00
52-wk high
8,54 $
52-wk low
2,29 $
EPS
-0,87 $
Beta
0,59
Shares outstanding
45,24 млн
No. of employees
26
Open
2,53 $
High
2,54 $
Low
2,48 $
Mkt. cap
113,79 млн
Avg. vol.
249,28 м.
Volume
0,00
52-wk high
8,54 $
52-wk low
2,29 $
EPS
-0,87 $
Beta
0,59
Shares outstanding
45,24 млн
No. of employees
26
News stories
From web sources and news partners
https://www.dars.gov.et/
·
1 ай бұрын
GNLX Q2 2026 Earnings: Wider-than-Expected Loss Reflects Continued Clinical Investment - Consensus Miss Rate
Profile
Genelux Corporation is a publicly traded late clinical-stage company developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
About Genelux Corp
CEO-
Employees26
Founded2001
HeadquartersWestlake Village, Калифорния, Америка Құрама Штаттары
Sector-
Websitegenelux.com